Shopping Cart

Your shopping cart is currently empty

Ibudilast

Name: Ibudilast
Brand: TargetMol
SKU: T2137
Price: 39 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T2137Cas No. 50847-11-5

Alias MN-166, KC-404, AV-411

Ibudilast (MN-166)(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor. It is approved for use as an anti-inflammatory in Japan.

Ibudilast

Copy Product Info

🥰Excellent

Purity: 99.96%

Catalog No. T2137Alias MN-166, KC-404, AV-411Cas No. 50847-11-5

Ibudilast (MN-166)(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor. It is approved for use as an anti-inflammatory in Japan.

Pack Size	Price	USA Warehouse	Global Warehouse
10 mg	$39	In Stock	In Stock
25 mg	$48	In Stock	In Stock
50 mg	$52	In Stock	In Stock
100 mg	$78	In Stock	In Stock
200 mg	$101	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$45	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.96%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Ibudilast AI Summary

Ibudilast exhibits a diverse range of bioactivities. It shows potent inhibitory activity against multiple phosphodiesterase (PDE) isoforms, including PDE4A, PDE4B, PDE4C, and PDE4D, with IC50 values ranging from 54.0 nM to 239.0 nM, suggesting potential therapeutic applications related to PDE4 inhibition. It also exhibits moderate inhibitory effects on LPS-induced TNFalpha release and fMLP-induced LTB4 biosynthesis in human whole blood, with IC50 values of 6200.0 nM and 2500.0 nM, respectively, indicating potential anti-inflammatory and immunomodulatory properties. Ibudilast shows inhibitory activity against human FAAH at 1 uM with 6.03% inhibition. It also impacts the inhibition of U-46619 induced contraction of guinea pig trachea by 64.5% at a concentration of 3*10e-8 M. Furthermore, Ibudilast demonstrates anti-viral activity, inhibiting SARS-CoV-2 induced cytotoxicity in VERO-6 cells with variable inhibition percentages ranging from 0.11% to 0.47% and demonstrated activity as a SARS-CoV-2 3CL-Pro protease inhibitor. In addition, it shows non-competitive inhibition of recombinant human MIF with a Ki of 30900.0 nM, and a binding affinity (Kd) of 1400.0 nM. The compound also marginally affects the activity of various human enzymes, including HDAC6, and exhibits significant inhibitory effects on human PDE3, PDE10, and PDE11 with IC50 values of ≤ 10000.0 nM. These bioactivities suggest that Ibudilast could have diverse pharmacological applications, including potential treatments for inflammatory and viral diseases..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ibudilast (MN-166)(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor. It is approved for use as an anti-inflammatory in Japan.
Targets&IC50	PDE5:2.2 μM, PDE4:0.08 μM, PDE2:0.11 μM
Synonyms	MN-166, KC-404, AV-411

Chemical Properties

Molecular Weight	230.31
Formula	C₁₄H₁₈N₂O
Cas No.	50847-11-5
Smiles	C(C(C)C)(=O)C1=C2N(N=C1C(C)C)C=CC=C2
Relative Density.	1.09

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 60 mg/mL (260.52 mM), Sonication is recommended.

Ethanol: 23 mg/mL (99.87 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.68 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	4.3420 mL	21.7099 mL	43.4197 mL	217.0987 mL
5 mM	0.8684 mL	4.3420 mL	8.6839 mL	43.4197 mL
10 mM	0.4342 mL	2.1710 mL	4.3420 mL	21.7099 mL
20 mM	0.2171 mL	1.0855 mL	2.1710 mL	10.8549 mL
50 mM	0.0868 mL	0.4342 mL	0.8684 mL	4.3420 mL

DMSO

	1mg	5mg	10mg	50mg
100 mM	0.0434 mL	0.2171 mL	0.4342 mL	2.1710 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc